GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » PRA Health Sciences Inc (NAS:PRAH) » Definitions » Equity-to-Asset

PRA Health Sciences (PRA Health Sciences) Equity-to-Asset : 0.36 (As of Mar. 2021)


View and export this data going back to 2014. Start your Free Trial

What is PRA Health Sciences Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. PRA Health Sciences's Total Stockholders Equity for the quarter that ended in Mar. 2021 was $1,557 Mil. PRA Health Sciences's Total Assets for the quarter that ended in Mar. 2021 was $4,283 Mil. Therefore, PRA Health Sciences's Equity to Asset Ratio for the quarter that ended in Mar. 2021 was 0.36.

The historical rank and industry rank for PRA Health Sciences's Equity-to-Asset or its related term are showing as below:

PRAH' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.18   Med: 0.31   Max: 0.36
Current: 0.36

During the past 9 years, the highest Equity to Asset Ratio of PRA Health Sciences was 0.36. The lowest was 0.18. And the median was 0.31.

PRAH's Equity-to-Asset is not ranked
in the Medical Diagnostics & Research industry.
Industry Median: 0.58 vs PRAH: 0.36

PRA Health Sciences Equity-to-Asset Historical Data

The historical data trend for PRA Health Sciences's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PRA Health Sciences Equity-to-Asset Chart

PRA Health Sciences Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only 0.33 0.28 0.33 0.31 0.35

PRA Health Sciences Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.30 0.31 0.35 0.35 0.36

Competitive Comparison of PRA Health Sciences's Equity-to-Asset

For the Diagnostics & Research subindustry, PRA Health Sciences's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PRA Health Sciences's Equity-to-Asset Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, PRA Health Sciences's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where PRA Health Sciences's Equity-to-Asset falls into.



PRA Health Sciences Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

PRA Health Sciences's Equity to Asset Ratio for the fiscal year that ended in Dec. 2020 is calculated as

Equity to Asset (A: Dec. 2020 )=Total Stockholders Equity/Total Assets
=1479.185/4178.501
=0.35

PRA Health Sciences's Equity to Asset Ratio for the quarter that ended in Mar. 2021 is calculated as

Equity to Asset (Q: Mar. 2021 )=Total Stockholders Equity/Total Assets
=1556.522/4282.745
=0.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PRA Health Sciences  (NAS:PRAH) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


PRA Health Sciences Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of PRA Health Sciences's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


PRA Health Sciences (PRA Health Sciences) Business Description

Traded in Other Exchanges
N/A
Address
4130 ParkLake Avenue, Suite 400, Raleigh, NC, USA, 27612
PRA Health Sciences is a global contract research organization that provides drug development and clinical trial services to pharmaceutical and biotechnology firms. Its services run from early- to late-stage clinical trial outsourcing with varying levels of support, including one-off specialized staffing services to strategic partnerships where PRA handles nearly all aspects of the trial. In 2017, PRA acquired Symphony Health, a healthcare data and analytics provider. PRA's competitor, Icon, announced it will acquire PRA for $12 billion, which is scheduled to close in third-quarter 2021.
Executives
Michael J. Bonello officer: EVP & CFO 4130 PARKLAKE AVENUE, SUITE 400, RALEIGH NY 27612
Shannon Colin director, officer: President & CEO PRA INTERNATIONAL 12120 SUNSET HILLS ROAD, SUITE 600 RESTON VA 20190
Christopher L Gaenzle officer: EVP, CAO & General Counsel C/O INC RESEARCH HOLDINGS, INC., 3201 BEECHLEAF COURT, SUITE 600, RALEIGH NC 27604
Glen D. Stettin director C/O EXPRESS SCRIPTS HOLDING COMPANY, ONE EXPRESS WAY, ST. LOUIS MO 63121
Alexander George Dickinson director 31542 CATALINA AVE LAGUNA BEACH CA 92651
Jeffrey T Barber director 6501 WESTON PARKWAY, SUITE 200 CARY NC 27513
Matthew P. Young director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Linda S Grais director 86 ALEJANDRA AVE, ATHERTON CA 94027
James C Momtazee director 2884 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
George R Roberts 10 percent owner C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 2800 SAND HILL ROAD, MENLO PARK CA 94025
Kkr Pra Investors Gp Ii Llc 10 percent owner 9 WEST 57TH STREET, SUITE 4200 NEW YORK NY 10019
Kkr Pra Investors L.p. 10 percent owner 9 WEST 57TH STREET, SUITE 4200 NEW YORK NY 10019
Kkr Pra Investors Gp Llc 10 percent owner 9 WEST 57TH STREET, SUITE 4200 NEW YORK NY 10019
Kkr North America Xi Ltd 10 percent owner KOHLBERG KRAVIS ROBERTS & CO. L.P., 9 WEST 57TH STREET, SUITE 4200, NEW YORK NY 10019
Kkr North America Fund Xi L.p. 10 percent owner C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 30 HUDSON YARDS, NEW YORK NY 10001

PRA Health Sciences (PRA Health Sciences) Headlines

From GuruFocus